Lp(a)HORIZON Trial: Lowering Lipoprotein(a) by 78% Did Not Reduce Heart Attacks or Strokes
· techtimes.com · popularity 17/100 · 0 similar stories today · Chronic Conditions (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Phase 3 Lp(a)HORIZON trial: pelacarsen lowered Lp(a) by 78% in 8,322 patients but failed to reduce heart attacks, strokes, or cardiovascular death (HR 1.02, P=0.76).
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 14.